Compare · BSX vs PFSA
BSX vs PFSA
Side-by-side comparison of Boston Scientific Corporation (BSX) and Profusa Inc. (PFSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and PFSA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 23861.6x PFSA ($3.0M).
- PFSA has been more active in the news (16 items in the past 4 weeks vs 10 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 0 for PFSA).
- Company
- Boston Scientific Corporation
- Profusa Inc.
- Price
- $49.86+1.73%
- $4.94+14.62%
- Market cap
- $72.26B
- $3.0M
- 1M return
- +9.58%
- -
- 1Y return
- -53.13%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 16
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation
Latest PFSA
- Profusa Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Profusa Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
- Chief Financial Officer Knechtel Fred S. converted options into 301,991 shares (SEC Form 4)
- Chief Executive Officer Stover Jack E converted options into 301,991 shares (SEC Form 4)
- SEC Form 10-Q filed by Profusa Inc.
- Large owner Hrt Financial Lp sold $109,266 worth of shares (18,395 units at $5.94), closing all direct ownership in the company (SEC Form 4)
- SEC Form PRE 14A filed by Profusa Inc.
- Large owner Hrt Financial Lp sold $2,853 worth of shares (3,163 units at $0.90), decreasing direct ownership by 4% to 71,035 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $5,384 worth of shares (5,585 units at $0.96) and sold $37,661 worth of shares (42,411 units at $0.89), decreasing direct ownership by 33% to 74,198 units (SEC Form 4)